Patents by Inventor Robert Seder

Robert Seder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210213126
    Abstract: Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFN?, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFN?, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a Mycobacterium tuberculosis (MTB) infection.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 15, 2021
    Inventors: Alexander K. Shalek, Travis Hughes, Marc H. Wadsworth, Robert Seder, Mario Roederer, Joanne L. Flynn, Patricia Darrah
  • Patent number: 11021535
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: June 1, 2021
    Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Sanaria Inc.
    Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
  • Publication number: 20210023208
    Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.
    Type: Application
    Filed: October 6, 2020
    Publication date: January 28, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Robert Seder, Geoffrey Lynn, Leonard Seymour
  • Publication number: 20210000934
    Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.
    Type: Application
    Filed: June 22, 2020
    Publication date: January 7, 2021
    Applicants: Oxford University Innovation Limited, The U.S.A., as Represented by the Secretary, Department of Health and Human Services
    Inventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
  • Patent number: 10799580
    Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: October 13, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Robert Seder, Geoffrey Lynn, Leonard Seymour
  • Publication number: 20190375831
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Application
    Filed: February 12, 2018
    Publication date: December 12, 2019
    Applicants: HUMAN SERVICES, SANARIA INC
    Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
  • Publication number: 20190060435
    Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.
    Type: Application
    Filed: February 27, 2017
    Publication date: February 28, 2019
    Applicant: The United States of America, as represented by the Secretary, Dept of Health and Human Service
    Inventors: Robert Seder, Geoffrey Lynn
  • Patent number: 10197577
    Abstract: Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 5, 2019
    Assignees: Sanaria Inc., Antigen Discovery, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Philip Felgner, Stephen L. Hoffman, Robert Seder, Joseph J. Campo, Jr.
  • Publication number: 20180280497
    Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.
    Type: Application
    Filed: September 9, 2016
    Publication date: October 4, 2018
    Applicants: The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Robert SEDER, Geoffrey LYNN, Leonard SEYMOUR
  • Publication number: 20180231566
    Abstract: Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.
    Type: Application
    Filed: December 29, 2017
    Publication date: August 16, 2018
    Applicants: Sanaria Inc., Antigen Discovery, Inc., The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Philip FELGNER, Stephen L. HOFFMAN, Robert SEDER, Joseph J. CAMPO, JR.
  • Publication number: 20170304420
    Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 26, 2017
    Applicants: Oxford University Innovation Limited, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
  • Publication number: 20160320404
    Abstract: Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.
    Type: Application
    Filed: March 4, 2016
    Publication date: November 3, 2016
    Applicants: Sanaria Inc., Antigen Discovery, Inc., The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Philip FELGNER, Stephen L. HOFFMAN, Robert SEDER, Joseph J. CAMPO, Jr.
  • Publication number: 20160216276
    Abstract: Disclosed herein are diagnostic assays for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The assays comprise the use of proteomes representing at least 50% of Pf, preferably coupled to a solid phase as a fixed array. The arrays are used to probe the sera of human subjects, particularly subjects of human clinical trials of whole parasite malaria vaccines as well as public health vaccination campaigns. Serum samples with antibody profiles most strongly reactive in multiplex to CSP and MSP5 demonstrate a sensitivity of from 92% to 100% and a specificity of from 84% to 89%.
    Type: Application
    Filed: September 2, 2014
    Publication date: July 28, 2016
    Inventors: Philip FELGNER, Stephen L. HOFFMAN, Robert SEDER
  • Publication number: 20060045885
    Abstract: The present invention provides methods of eliciting an immune response against HIV. Generally, the method includes administering to a subject an effective amount of an IRM-HIV composition that includes an IRM portion paired with an HIV antigenic portion.
    Type: Application
    Filed: August 26, 2005
    Publication date: March 2, 2006
    Inventors: Ross Kedl, Robert Seder